Skip Navigation


Japanese Journal of Clinical Oncology Advance Access originally published online on July 22, 2006
Japanese Journal of Clinical Oncology 2006 36(9):564-569; doi:10.1093/jjco/hyl063
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
36/9/564    most recent
hyl063v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Takayama, T.
Right arrow Articles by Ozono, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Takayama, T.
Right arrow Articles by Ozono, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© 2006 Foundation for Promotion of Cancer Research

High Levels of Thymidine Phosphorylase as an Independent Prognostic Factor in Renal Cell Carcinoma

Tatsuya Takayama1, Soichi Mugiya1, Takayuki Sugiyama1, Takahiro Aoki1, Hiroshi Furuse1, Hongming Liu1, Yasuhiro Hirano2, Fumitake Kai3, Tomomi Ushiyama1 and Seiichiro Ozono1

1 Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, 2 Fujieda Municipal General Hospital, Fujieda, Shizuoka and 3 Haibara General Hospital, Makinohara, Shizuoka, Japan

For reprints and all correspondence: Tatsuya Takayama, Department of Urology, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu, Shizuoka 431-3192, Japan. E-mail: takayama{at}hama-med.ac.jp

Received April 3, 2006; accepted May 21, 2006

Background: We investigated whether thymidine phosphorylase (TP) protein level in renal cell carcinoma (RCC) correlates with clinicopathological characteristics and clinical outcomes.

Methods: TP protein level was measured in 116 RCC specimens and in 90 non-neoplastic kidney tissues using a sandwich-type enzyme-linked immunosolvent assay.

Results: The median TP protein level in RCC tissues was 9.76-fold (range, 3.2–933.9) higher than those in non-neoplastic kidney tissues (P < 0.0001). TP protein level was correlated with T classification, histological grade and mode of infiltration. TP as a prognostic variable was studied using a logistic regression model. TP at higher levels (128 U/mg protein or greater) would play a role as an independent prognostic factor (odds ratio, 13.73; 95% confidence interval, 2.09–90.41; P = 0.0064).

Conclusion: TP at high levels can be regarded as an unfavorable independent prognostic factor. These results may pave a way for a novel approach to effective treatment of RCC.

Key Words: renal cell carcinoma • thymidine phosphorylase • prognostic factor


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.